REFERENCES


34. Stanley JR, Klaus Kovtun V, Sampaio SA: Antigenic specificity of fogo selvagem autoantibodies is similar to North American pemphigus foliaceus and distinct from pemphigus vulgaris autoantibodies. *J Invest Dermatol* 87:197, 1986


45. Ding X et al: The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. *J Invest Dermatol* 112:739, 1999


69. Aoyama Y, Kitajima Y: Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 112:67, 1999


84. Pavoni DP et al: Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes. Genes Immun 4:110, 2003


91. Veldman C et al: Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol 172:6468, 2004


112. Senear FE, Usher B: An unusual type of pemphigus combining features of lupus erythematosus. Arch Dermatol Syphilol 137:761, 1926


145. Tsuji Y et al: Clinical and serological transition from pemphigus vulgaris to pemphigus foliaceus demonstrated by desmoglein ELISA system. *Arch Dermatol* **138**:95, 2002


173. Roche Pharmaceuticals: Cellcept prescribing information. 2007


190. Li N et al: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440, 2005


201. Werth VP: Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. *Arch Dermatol* **132:**1435, 1996


203. Mentink LF et al: Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. *Arch Dermatol* **142:**570, 2006